Freeline, Symbiosis and the Cell and Gene Therapy Catapult have secured £1.3m funding from Innovate UK. Symbiosis and CGTC will create an innovative UK-based novel viral vector supply chain solution optimised for the Freeline Adeno Associated Virus manufacturing platform to accelerate Freeline’s production cycle by over 25% and the progression of its therapies into the clinic.
Chief executive Officer at CGT Catapult, Keith Thompson, said: “There has been a significant increase in the use of adeno-associated virus vectors in gene therapy trials, however producing these vectors at the required scale and throughput is still a barrier to industry growth. We are proud to support and accelerate the development of these exciting next generation therapies by working with Freeline and Symbiosis at the CGT Catapult manufacturing centre, providing access to our knowledge and expertise in viral vector manufacturing and the associated supply chain.”
“Innovate UK grants £1.3M funding to viral vector supply chain collaboration.“
Chief development officer at Freeline, Jan Thirkettle, said: “At Freeline we have developed a state-of-the-art AAV drug substance manufacturing process. With the launch of this collaboration, and the access to dedicated funding, we and our partners will be able to accelerate delivery of our portfolio and deliver high quality gene therapy products more rapidly to the clinic.”
Symbiosis CEO, Colin MacKay, said: “We have invested heavily to establish viral vector manufacturing capabilities with the aim of developing a UK-based supply chain to both facilitate and accelerate the successful clinical and commercial manufacture of viral vectors. Our well-established track record in viral vector fill finish for clinical trials positions Symbiosis perfectly to work with Freeline and CGTC on this project and help grow the UK’s expanding capabilities in the field of advanced therapy manufacturing.”